HSV-2 serologic testing in an HMO population: Uptake and psychosocial sequelae

Julie Richards, Delia Scholes, Selin Caka, Linda Drolette, Amalia Meier Magaret, Patty Yarbro, William Lafferty, Richard Crosby, Ralph DiClemente, Anna Wald

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: To prospectively measure the uptake of Herpes simplex virus Type 2 (HSV-2) testing and psychosocial response to a new serologic diagnosis of HSV-2 in a health maintenance organization (HMO) population. STUDY DESIGN: Randomly selected urban HMO enrollees were invited to be tested for HSV-2 antibody at a research clinic. Participants had blood drawn and completed demographic and psychosocial questionnaires. RESULTS: Of 3111 eligible enrollees contacted, 344 (11%) were tested. Eighty-seven (26%) tested HSV-2 seropositive, and 44 (51%) of these did not report a prior genital herpes diagnosis. Distress, measured by the total mood disturbance, was 6.5 points higher on average following a new genital herpes diagnosis relative to baseline (actual range = 109 points, P = 0.003) but not statistically different from HSV-2 negative or previously diagnosed participants. CONCLUSIONS: HMO enrollees unexpectedly testing HSV-2 positive showed short-term psychosocial distress that resolved during 6-month follow-up. Findings suggest that concerns about psychosocial burden should not deter voluntary serologic HSV-2 testing in primary care settings.

Original languageEnglish (US)
Pages (from-to)718-725
Number of pages8
JournalSexually Transmitted Diseases
Volume34
Issue number9
DOIs
StatePublished - Sep 1 2007

Fingerprint

Human Herpesvirus 2
Health Maintenance Organizations
Population
Herpes Genitalis
Urban Health
Primary Health Care
Demography
Antibodies
Research

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Richards, J., Scholes, D., Caka, S., Drolette, L., Magaret, A. M., Yarbro, P., ... Wald, A. (2007). HSV-2 serologic testing in an HMO population: Uptake and psychosocial sequelae. Sexually Transmitted Diseases, 34(9), 718-725. https://doi.org/10.1097/01.olq.0000261455.60955.59

HSV-2 serologic testing in an HMO population : Uptake and psychosocial sequelae. / Richards, Julie; Scholes, Delia; Caka, Selin; Drolette, Linda; Magaret, Amalia Meier; Yarbro, Patty; Lafferty, William; Crosby, Richard; DiClemente, Ralph; Wald, Anna.

In: Sexually Transmitted Diseases, Vol. 34, No. 9, 01.09.2007, p. 718-725.

Research output: Contribution to journalArticle

Richards, J, Scholes, D, Caka, S, Drolette, L, Magaret, AM, Yarbro, P, Lafferty, W, Crosby, R, DiClemente, R & Wald, A 2007, 'HSV-2 serologic testing in an HMO population: Uptake and psychosocial sequelae', Sexually Transmitted Diseases, vol. 34, no. 9, pp. 718-725. https://doi.org/10.1097/01.olq.0000261455.60955.59
Richards, Julie ; Scholes, Delia ; Caka, Selin ; Drolette, Linda ; Magaret, Amalia Meier ; Yarbro, Patty ; Lafferty, William ; Crosby, Richard ; DiClemente, Ralph ; Wald, Anna. / HSV-2 serologic testing in an HMO population : Uptake and psychosocial sequelae. In: Sexually Transmitted Diseases. 2007 ; Vol. 34, No. 9. pp. 718-725.
@article{d0cfcfbf1eb046f58b63d70ed4d755c5,
title = "HSV-2 serologic testing in an HMO population: Uptake and psychosocial sequelae",
abstract = "OBJECTIVES: To prospectively measure the uptake of Herpes simplex virus Type 2 (HSV-2) testing and psychosocial response to a new serologic diagnosis of HSV-2 in a health maintenance organization (HMO) population. STUDY DESIGN: Randomly selected urban HMO enrollees were invited to be tested for HSV-2 antibody at a research clinic. Participants had blood drawn and completed demographic and psychosocial questionnaires. RESULTS: Of 3111 eligible enrollees contacted, 344 (11{\%}) were tested. Eighty-seven (26{\%}) tested HSV-2 seropositive, and 44 (51{\%}) of these did not report a prior genital herpes diagnosis. Distress, measured by the total mood disturbance, was 6.5 points higher on average following a new genital herpes diagnosis relative to baseline (actual range = 109 points, P = 0.003) but not statistically different from HSV-2 negative or previously diagnosed participants. CONCLUSIONS: HMO enrollees unexpectedly testing HSV-2 positive showed short-term psychosocial distress that resolved during 6-month follow-up. Findings suggest that concerns about psychosocial burden should not deter voluntary serologic HSV-2 testing in primary care settings.",
author = "Julie Richards and Delia Scholes and Selin Caka and Linda Drolette and Magaret, {Amalia Meier} and Patty Yarbro and William Lafferty and Richard Crosby and Ralph DiClemente and Anna Wald",
year = "2007",
month = "9",
day = "1",
doi = "10.1097/01.olq.0000261455.60955.59",
language = "English (US)",
volume = "34",
pages = "718--725",
journal = "Sexually Transmitted Diseases",
issn = "0148-5717",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - HSV-2 serologic testing in an HMO population

T2 - Uptake and psychosocial sequelae

AU - Richards, Julie

AU - Scholes, Delia

AU - Caka, Selin

AU - Drolette, Linda

AU - Magaret, Amalia Meier

AU - Yarbro, Patty

AU - Lafferty, William

AU - Crosby, Richard

AU - DiClemente, Ralph

AU - Wald, Anna

PY - 2007/9/1

Y1 - 2007/9/1

N2 - OBJECTIVES: To prospectively measure the uptake of Herpes simplex virus Type 2 (HSV-2) testing and psychosocial response to a new serologic diagnosis of HSV-2 in a health maintenance organization (HMO) population. STUDY DESIGN: Randomly selected urban HMO enrollees were invited to be tested for HSV-2 antibody at a research clinic. Participants had blood drawn and completed demographic and psychosocial questionnaires. RESULTS: Of 3111 eligible enrollees contacted, 344 (11%) were tested. Eighty-seven (26%) tested HSV-2 seropositive, and 44 (51%) of these did not report a prior genital herpes diagnosis. Distress, measured by the total mood disturbance, was 6.5 points higher on average following a new genital herpes diagnosis relative to baseline (actual range = 109 points, P = 0.003) but not statistically different from HSV-2 negative or previously diagnosed participants. CONCLUSIONS: HMO enrollees unexpectedly testing HSV-2 positive showed short-term psychosocial distress that resolved during 6-month follow-up. Findings suggest that concerns about psychosocial burden should not deter voluntary serologic HSV-2 testing in primary care settings.

AB - OBJECTIVES: To prospectively measure the uptake of Herpes simplex virus Type 2 (HSV-2) testing and psychosocial response to a new serologic diagnosis of HSV-2 in a health maintenance organization (HMO) population. STUDY DESIGN: Randomly selected urban HMO enrollees were invited to be tested for HSV-2 antibody at a research clinic. Participants had blood drawn and completed demographic and psychosocial questionnaires. RESULTS: Of 3111 eligible enrollees contacted, 344 (11%) were tested. Eighty-seven (26%) tested HSV-2 seropositive, and 44 (51%) of these did not report a prior genital herpes diagnosis. Distress, measured by the total mood disturbance, was 6.5 points higher on average following a new genital herpes diagnosis relative to baseline (actual range = 109 points, P = 0.003) but not statistically different from HSV-2 negative or previously diagnosed participants. CONCLUSIONS: HMO enrollees unexpectedly testing HSV-2 positive showed short-term psychosocial distress that resolved during 6-month follow-up. Findings suggest that concerns about psychosocial burden should not deter voluntary serologic HSV-2 testing in primary care settings.

UR - http://www.scopus.com/inward/record.url?scp=34548164119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548164119&partnerID=8YFLogxK

U2 - 10.1097/01.olq.0000261455.60955.59

DO - 10.1097/01.olq.0000261455.60955.59

M3 - Article

VL - 34

SP - 718

EP - 725

JO - Sexually Transmitted Diseases

JF - Sexually Transmitted Diseases

SN - 0148-5717

IS - 9

ER -